GE HealthCare Technologies Inc. Third Quarter 2024 Earnings Conference Call Overview

In the recent Q3 2024 Earnings Conference Call, CEO Peter Arduini updated on GE HealthCare Technologies Inc. (NASDAQ:GEHC) financial performance and outlook. The company reported 1% organic revenue growth, totaling $4.9 billion in revenue, congruent with expectations. Service revenue increased by 2%, while product revenue remained stable. The backlog reached $19.6 billion, largely fueled by service contracts. The adjusted EBIT margin rose to 16.3%, with adjusted EPS growing to $1.14, a 15% year-over-year increase.

Key Takeaways

• Organic revenue growth: 1%, total revenues: $4.9 billion.
• Service revenue: up 2%, product revenue stable.
• Excluding China: sales growth around 5%.
• Backlog: increased to $19.6 billion, primarily from services.
• Adjusted EBIT margin: improved to 16.3%; adjusted EPS up to $1.14.
• Full-year guidance: adjusted EBIT margin raised to 15.8%-16% and adjusted EPS to $4.25-$4.35.
• Free cash flow: projected to be approximately $1.8 billion.
• Flyrcado launch: anticipated in early 2025 with expected annual revenues exceeding $500 million.
• Investment in AI and cloud solutions like CareIntellect is ongoing.

Company Outlook

• 2024 organic revenue growth: projected at the lower end of 1% to 2% guidance.
• Adjusted EPS guidance: increased to $4.25-$4.35.
• Free cash flow: expected around $1.8 billion.
• Investor Day: scheduled for November 21 to discuss growth strategies.

Challenges and Optimism

Bearish Highlights

• Ongoing challenges in the Chinese market due to delayed stimulus funding hinder near-term growth.
• Expecting a high teens decline in full-year sales for China, with limited stimulus benefits expected in the first half of 2025.

Bullish Highlights

• Strong growth in the U.S. market across all segments.
• Positive long-term outlook for the Chinese market.
• Significant advancements expected in Theranostics and FDA clearances for new tools.
• Flyrcado set to significantly impact revenue in cardiology.
• Anticipated changes in CMS reimbursement will support innovation.

Misses

• Guidance reduction of $400 million to $600 million at the midpoint attributed to underperformance in China.
• Full-year sales in China anticipated to decline in the high teens.

Q&A Highlights

• Flyrcado: likely priced at a premium due to advanced capabilities.
• Vizamyl sales: in the U.S. nearly doubled quarter-over-quarter.
• Anticipated CMS reimbursement changes could significantly increase rates.
• R&D growth will align closer with sales growth next year.

Conclusion: GE HealthCare is navigating market challenges, prioritizing strategic investments in new products and technologies that promise future growth. The company's focus on AI and innovative diagnostics strengthens its market position. Investors and observers await insights during the upcoming Investor Day on November 21, 2023.